BACKGROUND: The aim of this study was to investigate the clinical characteristics associated with invasive lobular cancer (ILC) and mixed invasive ductal cancer (IDC) and ILC compared with IDC. METHODS: From 1996 to 2006, 4,336 patients with IDC, ILC, and mixed breast cancers were identified. Clinical variables were compared using chi(2) and Fisher's exact tests. Kaplan-Meier survival curves were constructed. RESULTS: Patients included 3,595 (83%) with IDC, 480 (11%) with ILC, and 261 (6%) with mixed cancers. Patients with ILC and mixed cancers were more likely to have low-grade and estrogen-positive and progesterone-positive tumors but were diagnosed at higher stages of disease compared with patients with IDC (P < .05 for each). Patients with IDC had the poorest 5-year (80%) and 10-year (61%) survival compared with patients with ILC (87% and 68%) and mixed (84% and 69%) cancers (P = .029). CONCLUSIONS: Although patients with ILC and "mixed" cancers are diagnosed with more advanced disease, their survival is superior to patients with IDC.
BACKGROUND: The aim of this study was to investigate the clinical characteristics associated with invasive lobular cancer (ILC) and mixed invasive ductal cancer (IDC) and ILC compared with IDC. METHODS: From 1996 to 2006, 4,336 patients with IDC, ILC, and mixed breast cancers were identified. Clinical variables were compared using chi(2) and Fisher's exact tests. Kaplan-Meier survival curves were constructed. RESULTS:Patients included 3,595 (83%) with IDC, 480 (11%) with ILC, and 261 (6%) with mixed cancers. Patients with ILC and mixed cancers were more likely to have low-grade and estrogen-positive and progesterone-positive tumors but were diagnosed at higher stages of disease compared with patients with IDC (P < .05 for each). Patients with IDC had the poorest 5-year (80%) and 10-year (61%) survival compared with patients with ILC (87% and 68%) and mixed (84% and 69%) cancers (P = .029). CONCLUSIONS: Although patients with ILC and "mixed" cancers are diagnosed with more advanced disease, their survival is superior to patients with IDC.
Authors: Otto Metzger-Filho; Arlindo R Ferreira; Rinath Jeselsohn; William T Barry; Deborah A Dillon; Jane E Brock; Ines Vaz-Luis; Melissa E Hughes; Eric P Winer; Nancy U Lin Journal: Oncologist Date: 2018-12-05
Authors: Lindsay A Williams; Hazel B Nichols; Katherine A Hoadley; Chiu Kit Tse; Joseph Geradts; Mary Elizabeth Bell; Charles M Perou; Michael I Love; Andrew F Olshan; Melissa A Troester Journal: Cancer Causes Control Date: 2017-11-09 Impact factor: 2.506
Authors: Qinghu Ren; Liying Zhang; Rachel Ruoff; Susan Ha; Jinhua Wang; Shilpa Jain; Victor Reuter; William Gerald; Dilip D Giri; Jonathan Melamed; Michael J Garabedian; Peng Lee; Susan K Logan Journal: Cancer Date: 2013-04-19 Impact factor: 6.860
Authors: Giovanni Ciriello; Michael L Gatza; Andrew H Beck; Matthew D Wilkerson; Suhn K Rhie; Alessandro Pastore; Hailei Zhang; Michael McLellan; Christina Yau; Cyriac Kandoth; Reanne Bowlby; Hui Shen; Sikander Hayat; Robert Fieldhouse; Susan C Lester; Gary M K Tse; Rachel E Factor; Laura C Collins; Kimberly H Allison; Yunn-Yi Chen; Kristin Jensen; Nicole B Johnson; Steffi Oesterreich; Gordon B Mills; Andrew D Cherniack; Gordon Robertson; Christopher Benz; Chris Sander; Peter W Laird; Katherine A Hoadley; Tari A King; Charles M Perou Journal: Cell Date: 2015-10-08 Impact factor: 41.582
Authors: Tatiane M G Oliveira; Jorge Elias; Andrea F Melo; Sara R Teixeira; Salomão C Filho; Larissa M Gonçalves; Francesca M Faria; Daniel G Tiezzi; Jurandyr M Andrade; Valdair Muglia Journal: Insights Imaging Date: 2014-03-16